Gene therapy for wet AMD: could this mean fewer eye injections?

NCT ID NCT04645212

Ongoing Disease control Sponsor: Adverum Biotechnologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 23 people with wet age-related macular degeneration who received a single dose of ADVM-022 gene therapy in an earlier trial. Researchers are checking how safe the treatment is over time and whether it continues to control the disease, potentially reducing the need for regular eye injections. The goal is to see if this one-time gene therapy can keep vision stable with less ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blindness (disorder) choroidal neovascularization eye disorder macular degeneration retinal degeneration retinal disorder wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WET AGE RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Adverum Clinical Site

Bakersfield, California, 93309, United States
Adverum Clinical Site

Beverly Hills, California, 90211, United States
Adverum Clinical Site

Lakewood, Colorado, 80228, United States
Adverum Clinical Site

Deerfield Beach, Florida, 33064, United States
Adverum Clinical Site

Reno, Nevada, 89502, United States
Adverum Clinical Site

Philadelphia, Pennsylvania, 19107, United States
Adverum Clinical Site

Nashville, Tennessee, 37203, United States
Adverum Clinical Site

Bellaire, Texas, 77401, United States
Adverum Clinical Site

The Woodlands, Texas, 77384, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.